Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19776487 | 1.00 | PRMT5 (0.36) | PRMT5WDR77S1PR4ALDH1A1LMNA | |
| SCHEMBL21468971 | 0.85 | PRMT5 (0.38) | PRMT5WDR77S1PR4ALDH1A1LMNA | |
| SCHEMBL21459911 | 0.83 | S1PR4 (0.37) | PRMT5WDR77S1PR4ALDH1A1LMNA | |
| SCHEMBL21459912 | 0.83 | S1PR4 (0.37) | PRMT5WDR77S1PR4ALDH1A1LMNA | |
| SCHEMBL21469022 | 0.81 | PRMT5 (0.43) | PRMT5WDR77S1PR4ALDH1A1LMNA | |
| SCHEMBL19775751 | 0.81 | PRMT5 (0.43) | PRMT5WDR77S1PR4ALDH1A1LMNA | |
| SCHEMBL5963778 | 0.74 | S1PR4 (0.52) | PRMT5WDR77S1PR4ALDH1A1LMNA | |
| SCHEMBL28723955 | 0.72 | DRD4 (0.39) | PRMT5WDR77S1PR4DRD4CYP19A1 | |
| SCHEMBL28723953 | 0.72 | DRD4 (0.39) | PRMT5WDR77S1PR4DRD4CYP19A1 | |
| SCHEMBL6211440 | 0.67 | ALDH1A1 (0.39) | PRMT5WDR77ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | PRMT5 848/4885WDR77 3832/4885S1PR4 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.